ADC Therapeutics
$28.049876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$28.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.61 (-2.13%) Today
$0.00 (0.00%) As of 7:59 PM EDT after-hours
Why Robinhood?
You can buy or sell ADCT and other stocks, options, ETFs, and crypto commission-free!
About ADCT
ADC Therapeutics SA, also called ADC Therapeutics, is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. Read More The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland. The listed name for ADCT is ADC Therapeutics SA.
Employees
127
Headquarters
Epalinges, Vaud
Founded
2011
Market Cap
2.15B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
330.62K
High Today
$29.32
Low Today
$27.95
Open Price
$29.31
Volume
117.43K
52 Week High
$56.59
52 Week Low
$26.58
Collections
ADCT Earnings
-$0.67
-$0.45
-$0.22
$0.00
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 2, Pre-Market